Pharma Bribery Risk Looms: Trump’s Feb 12 executive order paused enforcement of the Foreign Corrupt Practices Act, stirring fears of a bribery surge in global pharma deals. Industry watchdogs warn middlemen could exploit lax oversight, potentially inflating drug costs—STAT News flagged a decade of $1.34B in fines as context. Read more
Biotech Brain Drain Hits: A Feb 12 report revealed U.S. labs losing talent as NIH funding dropped 5%, pushing young scientists to Europe and Asia. Some call it a “fire sale” of expertise; others argue it’s overhyped—Nature says it threatens gene-editing pipelines. Read more
MedTech Approval Snag: FDA’s glitchy review process delayed three device approvals Feb 12—insiders pin it on staff cuts from last week’s 5,200 layoffs. Smaller firms are hit hardest; is this a hiccup or a sign of deeper chaos? Read more
Quick Take: Feb 12’s policy shakeup, talent exodus, and regulatory stumbles signal a turbulent start—tech’s the wildcard to watch.
